Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Brief Summary: The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).


Options:
A: Arm Label: Abatacept (ABA); Type: EXPERIMENTAL; Interventions: Drug: abatacept (ABA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept (ABA); Assigned to Arm(s): Abatacept (ABA) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
B: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
C: Arm Label: Adalimumab 80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 160/80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80/40 | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160/80/40 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 50 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: PBO-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Arm Label: GLM-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 50 mg Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance, GLM-I-Rsp-Golimumab 50 mg Maintenance, GLM-I-nonRsp-Golimumab 100 mg Maintenance, Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, PBO-I-nonRsp-Golimumab 100 mg Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance

Answer: B